Effects of bevacizumab on retinal function in isolated vertebrate retina. 2006

M Lüke, and M Warga, and F Ziemssen, and F Gelisken, and S Grisanti, and T Schneider, and C Lüke, and M Partsch, and K U Bartz-Schmidt, and P Szurman, and
University Eye Hospital, Centre for Ophthalmology, Eberhard-KarlsUniversity of Tuebingen, Schleichstrasse 12-16, D-72076, Tuebingen, Germany. matthias.lueke@med.uni-tuebingen.de

BACKGROUND Bevacizumab (Avastin) is a recombinant protein that targets vascular endothelial growth factor (VEGF). In vitro, bevacizumab inhibits VEGF induced cell proliferation and tissue factor production. Abnormal angiogenesis involving VEGF is a central event during the development of choroidal neovascularisation (CNV). The present study was designed to evaluate the short term toxic effects of bevacizumab on retinal function for a therapeutic intraocular application. METHODS Isolated bovine retinas were perfused with an oxygen pre-incubated nutrient solution. The electroretinogram (ERG) was recorded as a transretinal potential using silver/silver chloride electrodes. Bevacizumab was added in different concentrations to the nutrient solution for 45 minutes. Thereafter the retina was reperfused for 60 minutes with normal nutrient solution. The percentage of a-wave and b-wave reduction during the application of bevacizumab was calculated and compared to control recordings. RESULTS During the application of three different concentrations of bevacizumab (0.08 mg/ml, 0.25 mg/ml, 0.8 mg/ml) no significant reduction of the a-wave and b-wave amplitude was observed. During the washout, the ERG amplitudes were unchanged. CONCLUSIONS The present study suggests that an intraocular application of 0.25 mg/ml bevacizumab for the treatment of CNV is reasonable. No significant short term effects of bevacizumab on retinal function were detected, but long term effects cannot be excluded.

UI MeSH Term Description Entries
D012160 Retina The ten-layered nervous tissue membrane of the eye. It is continuous with the OPTIC NERVE and receives images of external objects and transmits visual impulses to the brain. Its outer surface is in contact with the CHOROID and the inner surface with the VITREOUS BODY. The outer-most layer is pigmented, whereas the inner nine layers are transparent. Ora Serrata
D002417 Cattle Domesticated bovine animals of the genus Bos, usually kept on a farm or ranch and used for the production of meat or dairy products or for heavy labor. Beef Cow,Bos grunniens,Bos indicus,Bos indicus Cattle,Bos taurus,Cow,Cow, Domestic,Dairy Cow,Holstein Cow,Indicine Cattle,Taurine Cattle,Taurus Cattle,Yak,Zebu,Beef Cows,Bos indicus Cattles,Cattle, Bos indicus,Cattle, Indicine,Cattle, Taurine,Cattle, Taurus,Cattles, Bos indicus,Cattles, Indicine,Cattles, Taurine,Cattles, Taurus,Cow, Beef,Cow, Dairy,Cow, Holstein,Cows,Dairy Cows,Domestic Cow,Domestic Cows,Indicine Cattles,Taurine Cattles,Taurus Cattles,Yaks,Zebus
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004596 Electroretinography Recording of electric potentials in the retina after stimulation by light. Electroretinographies
D000068258 Bevacizumab An anti-VEGF humanized murine monoclonal antibody. It inhibits VEGF RECEPTORS and helps to prevent PATHOLOGIC ANGIOGENESIS. Avastin,Bevacizumab-awwb,Mvasi,Bevacizumab awwb
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D046509 Tissue Culture Techniques A technique for maintaining or growing TISSUE in vitro, usually by DIFFUSION, perifusion, or PERFUSION. The tissue is cultured directly after removal from the host without being dispersed for cell culture. Culture Technique, Tissue,Culture Techniques, Tissue,Tissue Culture Technique
D061067 Antibodies, Monoclonal, Humanized Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab. Antibodies, Humanized,Humanized Antibodies
D020533 Angiogenesis Inhibitors Agents and endogenous substances that antagonize or inhibit the development of new blood vessels. Angiogenesis Factor Inhibitor,Angiogenesis Inhibitor,Angiogenetic Antagonist,Angiogenetic Inhibitor,Angiogenic Antagonist,Angiogenic Antagonists,Angiogenic Inhibitor,Angiostatic Agent,Angiostatic Agents,Anti-Angiogenetic Agent,Anti-Angiogenic Drug,Anti-Angiogenic Drugs,Antiangiogenic Agent,Neovascularization Inhibitor,Neovascularization Inhibitors,Angiogenesis Factor Inhibitors,Angiogenetic Antagonists,Angiogenetic Inhibitors,Angiogenic Inhibitors,Antagonists, Angiogenic,Anti-Angiogenesis Effect,Anti-Angiogenesis Effects,Anti-Angiogenetic Agents,Antiangiogenesis Effect,Antiangiogenesis Effects,Antiangiogenic Agents,Inhibitors, Angiogenesis,Inhibitors, Angiogenetic,Inhibitors, Angiogenic,Inhibitors, Neovascularization,Agent, Angiostatic,Agent, Anti-Angiogenetic,Agent, Antiangiogenic,Agents, Angiostatic,Agents, Anti-Angiogenetic,Agents, Antiangiogenic,Antagonist, Angiogenetic,Antagonist, Angiogenic,Antagonists, Angiogenetic,Anti Angiogenesis Effect,Anti Angiogenesis Effects,Anti Angiogenetic Agent,Anti Angiogenetic Agents,Anti Angiogenic Drug,Anti Angiogenic Drugs,Drug, Anti-Angiogenic,Drugs, Anti-Angiogenic,Effect, Anti-Angiogenesis,Effect, Antiangiogenesis,Effects, Anti-Angiogenesis,Effects, Antiangiogenesis,Factor Inhibitor, Angiogenesis,Factor Inhibitors, Angiogenesis,Inhibitor, Angiogenesis,Inhibitor, Angiogenesis Factor,Inhibitor, Angiogenetic,Inhibitor, Angiogenic,Inhibitor, Neovascularization,Inhibitors, Angiogenesis Factor

Related Publications

M Lüke, and M Warga, and F Ziemssen, and F Gelisken, and S Grisanti, and T Schneider, and C Lüke, and M Partsch, and K U Bartz-Schmidt, and P Szurman, and
March 2010, Current eye research,
M Lüke, and M Warga, and F Ziemssen, and F Gelisken, and S Grisanti, and T Schneider, and C Lüke, and M Partsch, and K U Bartz-Schmidt, and P Szurman, and
October 2009, The British journal of ophthalmology,
M Lüke, and M Warga, and F Ziemssen, and F Gelisken, and S Grisanti, and T Schneider, and C Lüke, and M Partsch, and K U Bartz-Schmidt, and P Szurman, and
March 2017, Journal of current ophthalmology,
M Lüke, and M Warga, and F Ziemssen, and F Gelisken, and S Grisanti, and T Schneider, and C Lüke, and M Partsch, and K U Bartz-Schmidt, and P Szurman, and
April 2005, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics,
M Lüke, and M Warga, and F Ziemssen, and F Gelisken, and S Grisanti, and T Schneider, and C Lüke, and M Partsch, and K U Bartz-Schmidt, and P Szurman, and
April 2001, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics,
M Lüke, and M Warga, and F Ziemssen, and F Gelisken, and S Grisanti, and T Schneider, and C Lüke, and M Partsch, and K U Bartz-Schmidt, and P Szurman, and
January 2014, Ophthalmic research,
M Lüke, and M Warga, and F Ziemssen, and F Gelisken, and S Grisanti, and T Schneider, and C Lüke, and M Partsch, and K U Bartz-Schmidt, and P Szurman, and
August 2005, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics,
M Lüke, and M Warga, and F Ziemssen, and F Gelisken, and S Grisanti, and T Schneider, and C Lüke, and M Partsch, and K U Bartz-Schmidt, and P Szurman, and
January 2011, Ophthalmic research,
M Lüke, and M Warga, and F Ziemssen, and F Gelisken, and S Grisanti, and T Schneider, and C Lüke, and M Partsch, and K U Bartz-Schmidt, and P Szurman, and
April 2011, Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie,
M Lüke, and M Warga, and F Ziemssen, and F Gelisken, and S Grisanti, and T Schneider, and C Lüke, and M Partsch, and K U Bartz-Schmidt, and P Szurman, and
January 2015, Ophthalmic research,
Copied contents to your clipboard!